BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Cystic fibrosis clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for cystic fibrosis: 39 (27 sponsors; 9 newly posted in the last 180 days, 3 stopped in the last 180 days; 3 new-entrant sponsors). Momentum score 16.7, rank 38 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 11, Phase 2 15, Phase 3 7, Phase 4 0, N/A 6.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Vertex Pharmaceuticals Incorporated VERX8P1 3, P3 511
Haisco Pharmaceutical Group Co., Ltd.5P3 2, P1 342
Reistone Biopharma Company Limited new entrant2P1 221
4D Molecular Therapeutics FDMT1P2 100
Aimmune Nestlé Health Science US R&D, LLC1P2 100
Anagram Therapeutics, Inc.1P2 100
Arcturus Therapeutics, Inc. ARCT1P2 100
AstraZeneca AZN1NA 100
BiomX Ltd1P2 100
Boehringer Ingelheim1P2 100
ChromX Health1NA 101
Cognita Labs LLC1NA 100
CSL Behring1P2 100
Cystetic Medicines, Inc.1P1 100
iSono Health, Inc.1NA 100
Jiangsu HengRui Medicine Co., Ltd.1P2 100
Krystal Biotech, Inc. KRYS1P1 101
Paragonix Technologies1NA 100
Physio-Assist1NA 100
ReCode Therapeutics1P2 100
Revagenix, Inc. new entrant1P1 110
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.1P2 101
Spirovant Sciences, Inc.1P2 101
SpliSense Ltd.1P2 100
Thirty Respiratory Limited1P2 100

New-entrant sponsors: Reistone Biopharma Company Limited, Revagenix, Inc..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-28 est.P3Haisco Pharmaceutical Group Co., Ltd.NCT06660992 A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis BronchiectasisNon-cystic Fibrosis Bronchiectasisrecruiting669
2026-12-31 est.P1/P2Spirovant Sciences, Inc.NCT06526923 A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)Cystic Fibrosisrecruiting15
2027-01-08 est.P2Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT06981091 A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in PatiNon-Cystic Fibrosis Bronchiectasisactive not recruiting234

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2ReCode TherapeuticsNCT06237335 A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CFCystic Fibrosisactive not recruiting128
2026-10-30 est.P3Vertex Pharmaceuticals Incorporated VERXNCT05444257 A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyCystic Fibrosisactive not recruiting822
2026-06-25P2Sionna Therapeutics Inc. SIONNCT07108153 Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to TrikaftaCystic Fibrosis (CF)completed15

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "cystic fibrosis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.